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Abstract
Introduction Rapid diagnostic tests may allow early
identification of previously unknown methicillin-resistant
Staphylococcus aureus (MRSA) carriers at intensive care unit
(ICU) admission. The aim of this study was twofold: first, to
assess whether a new molecular MRSA screening test can
substantially decrease the time between ICU admission and
identification of MRSA carriers; and, second, to examine the
combined effect of rapid testing and pre-emptive contact
isolation on MRSA infections.
Method Since November 2003, patients admitted for longer
than 24 hours to two adult ICUs were screened systematically
on admission using quick, multiplex immunocapture-coupled
PCR (qMRSA). Median time intervals from admission to
notification of test results were calculated for a five-month
intervention phase (November 2003–March 2004) and
compared with a historical control period (April 2003–October
2003) by nonparametric tests. ICU-acquired MRSA infection
rates were determined for an extended surveillance period
(January 2003 through August 2005) and analyzed by Poisson
regression methods.
Results During the intervention phase, 97% (450/462) of
patients admitted to the surgical ICU and 80% (470/591) of
patients admitted to the medical ICU were screened. On-
admission screening identified the prevalence of MRSA to be
6.7% (71/1053). Without admission screening, 55 previously
unknown MRSA carriers would have been missed in both ICUs.
Median time from ICU admission to notification of test results
decreased from 87 to 21 hours in the surgical ICU (P < 0.001)
and from 106 to 23 hours in the medical ICU (P < 0.001). In the
surgical ICU, 1,227 pre-emptive isolation days for 245 MRSA-
negative patients were saved by using the qMRSA test. After
adjusting for colonization pressure, the systematic on-admission
screening and pre-emptive isolation policy was associated with
a reduction in medical ICU acquired MRSA infections (relative
risk 0.3, 95% confidence interval 0.1–0.7) but had no effect in
the surgical ICU (relative risk 1.0, 95% confidence interval 0.6–
1.7).
Conclusion The qMRSA test decreased median time to
notification from four days to one day and helped to identify
previously unknown MRSA carriers rapidly. A strategy linking the
rapid screening test to pre-emptive isolation and cohorting of
MRSA patients substantially reduced MRSA cross-infections in
the medical but not in the surgical ICU.
CI = confidence interval; ICU = intensive care unit; MRSA = methicillin-resistant Staphylococcus aureus; PCR = polymerase chain reaction; qMRSA 
= quick MRSA screening; RR = relative risk; TAT = turnaround time.Critical Care    Vol 10 No 1    Harbarth et al.
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Introduction
Nosocomial infections caused by methicillin-resistant Staphy-
lococcus aureus (MRSA) are associated with significant
adverse outcomes and increased health care costs [1].
Patients colonized with MRSA serve as a reservoir for spread
within the health care environment, mainly through the hands
of health care workers. Active surveillance by patient screen-
ing and intensive control measures represent attempts to
decrease this reservoir, with the ultimate goal of reducing
MRSA infection rates [2].
The most efficient approach to control of endemic MRSA
remains controversial [3-6]. Several authorities have sug-
gested that screening on admission to intensive care units
(ICUs) and subsequent patient isolation may decrease the risk
for MRSA cross-infection [7-11]. Rapid screening tests may
further improve MRSA control, because traditional microbio-
logical methods for MRSA screening are slow [12]. Delays in
receiving screening results means either that negative patients
remain isolated for too long or that positive patients remain a
hidden reservoir for cross-infection. With the availability of
rapid molecular MRSA screening methods, determining their
value in daily practice is of great importance.
The purpose of this study, conducted in two adult ICUs with
endemic MRSA, was to test the hypothesis that a new molec-
ular technique that enables early detection of MRSA carriage
can substantially decrease the time between ICU admission
and notification of screening results. In addition, we evaluated
the effect of a strategy combining early MRSA detection and
pre-emptive contact isolation on the rate of ICU-acquired
MRSA infections.
Materials and methods
Setting and study populations
The Geneva University Hospital, Switzerland, is a 2,200-bed
primary and tertiary medical centre, to which approximately
47,000 patients are admitted annually. The surgical ICU is an
18-bed referral unit, admitting 1,650 patients per year for
close observation and treatment after multiple trauma and
major surgery for a mean duration of 4.0 days. The medical
ICU has 18 beds, 1,700 admissions and an average length of
stay of 3.7 days. In 2002 the medical ICU had a nosocomial
MRSA acquisition rate of 2.5 new MRSA cases per 1,000
patient days, whereas the surgical ICU had 3.5 new cases per
1,000 patient days.
Study design and outcomes
This interventional cohort study compared a new molecular
technique enabling quick MRSA screening (qMRSA) with a
standard method in patients admitted to the two adult ICUs at
the Geneva University Hospital. From November 2003,
patients admitted for longer than 24 hours were screened sys-
tematically on ICU admission using the qMRSA test, which is
based on a multiplex immunocapture-coupled PCR, to identify
patients colonized with MRSA. Median time interval (in hours)
from ICU admission to notification of test results to ICU care
givers was the primary end-point, which was determined over
a five-month period (November 2003–March 2004; phase II)
and compared with a historical control period (April 2003–
October 2003; phase I), during which conventional culture
techniques were used. In phase I, on-admission screening was
performed only in those patients at high risk for MRSA carriage
(for example, with previously identified MRSA colonization or
transfer from a long-term care facility) [13,14].
ICU-acquired MRSA infection rates were determined for an
extended surveillance period (January 2003 through August
2005), which encompassed phase III (April 2004–August
2005). Systematic discharge screening was only introduced
in November 2003; therefore, it was not possible to evaluate
MRSA acquisition rates for the entire study period. Table 1
summarizes the different phases and interventions in the
study.
Table 1
Summary of the different phases and interventions during the study period
Period Surgical ICU Medical ICU
January 2003 to October 2003 (includes 
phase I, which started in April 2003)
Screening and pre-emptive isolation of high-
risk patients only
No discharge screening
Conventional culture methods
Screening of high-risk patients only
No pre-emptive isolation
No discharge screening
Conventional culture methods
November 2003 to March 2004 (phase II) Systematic on-admission and discharge 
screening policy
Extension of pre-emptive isolation to all 
patients
Rapid PCR technique for admission screening
Systematic on-admission and discharge 
screening policy
No pre-emptive isolation
Rapid PCR technique for admission screening
April 2004 to August 2005 (phase III) Systematic on-admission and discharge 
screening policy
General pre-emptive isolation
Rapid PCR technique for admission screening
Systematic on-admission and discharge 
screening policy
General pre-emptive isolation
Rapid PCR technique for admission screening
Note that contact isolation was implemented for all identified carriers of methicillin-resistant Staphylococcus aureus during the entire study period. 
No antibiotic restriction or hand hygiene education campaigns with systematic feedback were performed. ICU, intensive care unitAvailable online http://ccforum.com/content/10/1/R25
Page 3 of 8
(page number not for citation purposes)
Screening procedure
Swabs were taken using a cotton stick moistened with sterile
0.9% saline solution. They were collected from both anterior
nares and perineal region in all patients and, if positive, from
catheter insertion sites, skin lesions and urine in catheterized
patients [15,16]. The study was approved by the institutional
review board as a continuous quality improvement project,
providing direct benefit to involved patients. Informed consent
was therefore not required.
Microbiologic procedures
Conventional technique
Swabs were first streaked onto ORSA plates (Oxacillin Resist-
ance Screening Agar; Oxoid, Basingstoke, UK) and then sus-
pended in 2 ml colistin-salt broth (brain–heart infusion with 10
µg colistin/ml and 2.5% NaCl) as a backup media. Suspect
colonies were confirmed by Pastorex agglutination (Bio-Rad,
Reinach, Switzerland), positive reaction on DNase agar, and
growth on Mueller-Hinton oxacillin agar (6 µg oxacillin/ml). The
presence of MRSA was confirmed using the Vitek 2 identifica-
tion and susceptibility testing cards for Gram-positive bacteria
(bioMérieux, Marcy l'Etoile, France).
Workflow
Before the study we accelerated the workflow in the microbi-
ology laboratory to minimize turnaround times (TATs) of the
conventional method by optimizing laboratory organization and
selecting faster methods. Median TATs (time interval between
sample delivery to the laboratory and report of the results)
decreased subsequently from 101 hours (year 2000) to 73
hours (year 2002).
Rapid technique
The quick multiplex immunocapture-coupled quantitative PCR
allows for same-day diagnosis of MRSA carriage through
detection of the mecA gene (either in S. aureus or S. epider-
midis), even in the presence of samples heavily contaminated
by methicillin-resistant S. epidermidis [17]. Swab samples are
resuspended in a buffer, and then S. aureus is immunocap-
tured using monoclonal antibodies coupled to magnetic beads
and directed against protein A. After bacterial lysis, the pres-
ence of MRSA is assessed using a multiplexed real-time PCR
(qMRSA) assay, as previously described [17]. If mecA cannot
be linked to the presence of methicillin-resistant S. epider-
midis, then MRSA is reported to be present. qMRSA tests
were performed five days per week, excluding weekends.
Test characteristics
The diagnostic performance of the qMRSA test in critically ill
patients was assessed during a pilot phase before the start of
the present study. Results of conventional MRSA culturing
procedures, including a backup broth culture, were used as an
imperfect reference standard, because PCR-based tests are
known to yield more positive results than are cultures [18,19].
With a prevalence of MRSA carriage on admission of 14%
(31/219), the sensitivity and specificity of the qMRSA test
were 84% and 94%, respectively, compared with conven-
tional procedures, with a corresponding negative predictive
value of 97%. Analysis of false-negative qMRSA results (n =
5) indicated that they arose from samples where MRSA was
recovered from backup broth only.
Infection control procedures
In both ICUs, MRSA control measures included contact isola-
tion of identified MRSA carriers in rooms with flagged doors
and dedicated material (gowns, gloves, masks); spatial sepa-
ration of patients into cohorts in case of large clusters; topical
decolonization (nasal mupirocin ointment and antiseptic body
washing of known MRSA carriers for at least five days); a com-
puterized MRSA alert system; and regular feedback of surveil-
lance results [13,15,20].
Because of some earlier clusters of MRSA cross-transmission,
since 1999 the surgical ICU has applied a pre-emptive isola-
tion policy in patients at high risk for MRSA carriage on admis-
sion (for example, transfer from another health care facility)
[21]. In November 2003 (surgical ICU) and April 2004 (medi-
cal ICU), the ICUs introduced a general pre-emptive isolation
policy for all patients. Patients were presumptively placed
under contact precautions until the results of the qMRSA test
were found to be negative.
Data collection and methicillin-resistant 
Staphylococcus aureus surveillance
TATs for MRSA screening and work up were recorded for
study phases I and II (weekends and public holidays excluded)
with the help of computerized laboratory databases and stored
in a log file for the purpose of statistical analysis. Retrieved
parameters were the following time intervals (in hours): time
from ICU admission to MRSA screening; time from screening
to sample delivery to the laboratory; and time from arrival at the
laboratory to reporting of results. During phase III, detailed
TATs were not recorded.
MRSA infections were monitored by dedicated infection con-
trol nurses who visited the ICUs daily (excluding weekends)
and performed prospective surveillance of MRSA infections
using modified US Centers for Disease Control and Preven-
tion definitions [22]. The nurses screened a wide range of
data, gathered from medical records, nursing charts and
microbiology reports [23,24].
Definitions
MRSA infection was considered to be ICU acquired if the
patient developed the infection 48 hours after admission to
one of the ICUs and had not been colonized or infected with
MRSA within the previous week before ICU admission. A pre-
viously unknown MRSA case was defined as any patient in
whom MRSA was isolated for the first time on ICU admission
[16]. A pre-emptive isolation day was defined as a day in whichCritical Care    Vol 10 No 1    Harbarth et al.
Page 4 of 8
(page number not for citation purposes)
an ICU patient stayed under contact precautions while await-
ing the results of the on-admission MRSA screening. The inci-
dence rate of ICU-acquired MRSA infections was defined as
the number of newly identified patients with MRSA infection
divided by the number of patient days at risk [15].
Statistical analysis
Time intervals from admission to notification of test results
were expressed as medians and compared using nonparamet-
ric tests. To compare incidence rates of ICU-acquired MRSA
infections over time, Poisson regression analysis was per-
formed because rates were low [15,25]. This analysis
included data from January 2003 through August 2005. The
number of ICU-acquired MRSA infections in a given month
was the dependent variable. Only one MRSA infection was
considered per patient per ICU stay. Preintervention or postin-
tervention status (extension of pre-emptive isolation and intro-
duction of the qMRSA test to the surgical ICU; initiation of
qMRSA testing and pre-emptive isolation in the medical ICU)
was the primary independent variable. The monthly number of
admitted, previously known MRSA carriers was included in the
model as a second independent variable, to adjust for coloni-
zation pressure [26,27]. All analyses were performed using
STATA 8.0 (STATA Inc., College Station, TX, USA).
Results
Screening and methicillin-resistant Staphylococcus 
aureus carriage on admission
From April 2003 through March 2004, 2,369 patients (phase
I, n = 1,316; phase II, n = 1,053) were admitted for longer than
24 hours in both ICUs. The proportion of patients who were
screened on admission was 41% in phase I (536/1316) and
more than doubled in phase II (920/1,053; 87%). In the latter
phase, 450 out of 462 surgical ICU patients (97%) and 470
out of 591 medical ICU patients (80%) were screened. From
April 2004 (phase III), compliance with on-admission screen-
ing remained high in both units (>95%).
In phase II the monthly prevalence of MRSA carriage at the
time of ICU admission varied between 4.2% (9/213 screened
patients in February 2004) and 7.8% (17/219 screened
patients in January 2004). The overall on-admission preva-
lence of MRSA was 6.7% (71/1053). Without systematic on-
admission screening, 55 previously unknown MRSA carriers
would have been missed on admission to both ICUs.
Turnaround times
TATs were determined for 322 and 510 patients screened on
admission in phases I and II, respectively. Detailed time sav-
ings for both ICUs together are shown in Table 2. Median time
from ICU admission to notification of test results decreased
from 87 to 21 hours in the surgical ICU (P < 0.001) and from
106 to 23 hours in the medical ICU (P < 0.001). Of note, we
observed not only a reduction in laboratory TATs but also a
decrease in the time from admission to screening by advocat-
ing MRSA screening as high-priority action on admission.
During phase II, 245 MRSA-negative surgical ICU patients
would have spent 1227 additional days in pre-emptive isola-
tion if the culture-based screening technique had been used
for systematic on-admission screening. Thus, after implemen-
tation of systematic, pre-emptive isolation in this unit, a sub-
stantial amount of unnecessary isolation days was saved by
using the qMRSA test.
Methicillin-resistant Staphylococcus aureus infection 
rates
From January 2003 through August 2005, the overall inci-
dence of ICU-acquired MRSA infections was 1.96 and 4.14
per 1,000 patient days in the medical and surgical ICUs,
respectively. The corresponding rates for phase I were 2.7/
1,000 patient days (medical ICU) and 3.66/1,000 patient days
(surgical ICU), and for phase II they were 4.52/1,000 patient
days (medical ICU) and 4.45/1,000 patient days (surgical
ICU). As shown in Figure 1, no clear effect on MRSA infec-
tions was observed in both ICUs after introduction of the
qMRSA test and an increased frequency of screening on
admission (phase II). However, a substantial decrease of
MRSA infections was seen in the medical ICU after implemen-
tation of pre-emptive isolation measures in April 2004 (phase
III).
Thirty-two months of consecutive data were available for the
Poisson regression analysis. For the surgical ICU, 10 months
were used as the control period, whereas for the medical ICU
Table 2
Delay between ICU admission and notification of test results: 
standard culture versus qMRSA
Standard culture 
(phase I)
Rapid qMRSA 
test (phase II)
P
n 322 510 -
Time from 
admission to 
screening 
(hours)
13.4 (4.8–21.6) 6.3 (0.6–10.3) <0.001
Time from 
screening to 
arrival in the 
lab (hours)
3.2 (1.3–12.1) 3.6 (1.1–10.9) 0.82
Time from 
receipt in the 
lab to result 
notification 
(hours)
71.8 (47.9–94.6) 7.2 (6.3–22.2) <0.001
Total time 
(hours)
93.1 (73.2–118.9) 22.2 (16.7–27.6) <0.001
Note that weekends and public holidays were not included. Values 
are expressed as median (interquartile range). ICU, intensive care 
unit; qMRSA, quick methicillin-resistant Staphylococcus aureus 
screening.Available online http://ccforum.com/content/10/1/R25
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15 of the 32 months were before the initiation of pre-emptive
isolation and rapid on-admission screening. In the surgical ICU
model, MRSA colonization pressure was predictive of the
number of MRSA infections per month (relative risk [RR] per
one-patient increment 1.1, 95% confidence interval [CI] 1.0–
1.2; P = 0.02), whereas implementation of the qMRSA test
had no effect (RR 1.0, 95% CI 0.6–1.7; P = 0.97). The com-
bined intervention was a significant independent covariate in
the medical ICU model (RR 0.3, 95% CI 0.1–0.7; P = 0.004)
after adjusting for colonization pressure, indicating that the
Figure 1
Previously known MRSA carriage on admission versus ICU-acquired MRSA infection Previously known MRSA carriage on admission versus ICU-acquired MRSA infection. Shown are the numbers of patients with previously known 
MRSA carriage on admission (MRSA colonization pressure) and the numbers of patients with ICU-acquired MRSA infections (surgical and medical 
ICUs; Geneva University Hospitals; January 2003 through August 2005). (a) (upper panel) Medical ICU. The vertical line on the figure indicates the 
initiation of rapid on-admission screening in November 2003 (phase II). The dashed vertical line indicates the initiation of pre-emptive isolation for all 
patients in April 2004 (phase III). (b) (lower panel) Surgical ICU. The vertical line on the figure indicates the initiation of rapid MRSA screening on 
admission and extension of pre-emptive isolation in November 2003 (phase II). ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus 
aureus.Critical Care    Vol 10 No 1    Harbarth et al.
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systematic on-admission screening and pre-emptive isolation
strategy was associated with a reduced rate of medical ICU
acquired MRSA infections during phase III.
Characteristics of methicillin-resistant Staphylococcus 
aureus positive patients during phase II
During phase II (November 2003 through March 2004), we
collected additional patient-level information on 106 patients
with imported or ICU-acquired MRSA. Only 13/106 (12%)
patients had their first MRSA isolate from a clinical culture,
whereas 71 (67%) were detected through on-admission
screening and 22 (21%) in other screening specimens during
the ICU stay or at discharge. The median time interval from
admission to the first positive MRSA culture in patients who
were MRSA-negative on admission was 5 days (range 2–22
days).
Among the 35 patients who were MRSA-negative at admis-
sion screening and acquired MRSA carriage during their ICU-
stay, 16 (46%) developed at least one MRSA infection. Over-
all, 22 of the 106 (21%) MRSA-positive patients acquired a
MRSA infection in one of the ICUs.
Discussion
Rapid MRSA screening tests can have an impact both at the
individual and group level because they can improve patient
outcomes by permitting early detection of MRSA carriage and
rapid contact isolation. The principal findings of this study eval-
uating a rapid MRSA test in critically ill patients are as follows.
ICU admission prevalence of previously unknown MRSA carri-
ers was high. Only a small minority of patients had their first
MRSA isolate from a routine clinical culture. The qMRSA test
decreased overall time to notification from four days to one day
and helped to identify previously unknown MRSA carriage rap-
idly. No effect on MRSA infection rates was observed in the
surgical ICU, although a large number of unnecessary pre-
emptive isolation days could be saved in this unit by using the
qMRSA test. Finally, a substantial decrease in MRSA infec-
tions was seen in the medical ICU after increasing compliance
with on-admission screening and linking the rapid test to pre-
emptive isolation and cohorting of MRSA patients.
Despite the fact that culture-based MRSA screening tech-
niques have proven cheap and sensitive if samples are col-
lected from several body sites, the time to report the results
remains a major issue. Definitive identification and testing
results are usually available only 48 to 96 hours after sample
collection, a time delay that could allow MRSA cross-transmis-
sion if patients are not presumptively placed under contact
precautions [19,28]. This may be one of the reasons (apart
from low hand hygiene compliance) why the recently pub-
lished study by Cepeda and colleagues [4] did not identify a
significant effect of contact isolation for MRSA carriers identi-
fied by conventional methods [29].
This study is the first to report detailed time intervals from
patient admission to notification of MRSA test results in criti-
cally ill patients. Previous reports on rapid MRSA screening
tests only assessed the time of specimen processing, without
taking into account transport of specimens and the delay
between admission and screening [18,30-32]. Our findings
show that factors other than laboratory analysis may have an
effect on total time from admission to notification of test
results, and that efforts are warranted to reduce these delays.
The added value of providing molecular screening capability
during nights and weekends remains to be assessed.
The few investigations that specifically evaluated the preva-
lence of MRSA carriage on ICU admission differ from ours in
important ways, and so comparisons are limited. However, our
study confirms that the prevalence of previously unknown
MRSA carriage at admission to critical care is high in settings
with endemic MRSA transmission. Previously reported preva-
lences of MRSA carriage at ICU admission ranged between
6% and 34% [4,6,9,11,33-36]. In all of these studies, fewer
than 50% of MRSA carriers had previously been identified as
such, emphasizing the importance of early screening to detect
the unknown reservoir of MRSA patients.
Current limitations to routine implementation of PCR-based
MRSA screening tests are their high costs, the workload of
specimen processing and the lack of trained laboratory tech-
nicians. We do not yet have sufficient data to demonstrate the
cost-effectiveness of our rapid screening strategy. It is possi-
ble that MRSA control in the ICU setting may also be achieved
with fewer resources and without rapid screening tools [11].
Nevertheless, the rapid qMRSA test saved a large number of
unnecessary isolation days in the surgical ICU and helped to
decrease substantially MRSA infections in the medical ICU,
making it likely that this intervention saved costs for the hospi-
tal. In addition, by saving unnecessary isolation days, we might
have increased patient safety because isolation precautions
may decrease provider–patient interactions and increase the
rate of adverse events [37].
In a recently reported mathematical model it was suggested
that a policy of screening newly admitted patients for MRSA
coupled with rapid contact isolation could reduce nosocomial
MRSA infection [38]. However, despite systematic on-admis-
sion screening and pre-emptive contact isolation, the inci-
dence of MRSA infections did not decrease in the surgical
ICU. By contrast, the medical ICU had greater success with
MRSA control. This contradictory finding may reflect differ-
ences in case mix, frequency of patient movements outside the
ICU, or compliance with standard precautions and isolation
practices [39]. Antibiotic selection pressure is rather low in the
surgical ICU, making it unlikely that this factor confounded the
study results [40].Available online http://ccforum.com/content/10/1/R25
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Our study has limitations. First, we used a rapid MRSA test
that lacks perfect specificity and sensitivity. Therefore, we can-
not exclude the possibility that the test artificially increased the
number of isolation days needed due to false-positive qMRSA
test results. Moreover, there may have been patients with
false-negative screening results, in whom MRSA acquisition
was erroneously attributed to the ICU. Second, we did not per-
form discharge screening during the entire study period, mak-
ing it impossible to compare MRSA acquisition rates during
the different study phases. Third, although colonization pres-
sure was appropriately adjusted for, other potential confound-
ing factors (such as antibiotic use, compliance with hand
hygiene practices and isolation precautions, case-mix, or staff-
ing levels) were not adjusted for in the analysis. Because these
factors have been shown to fluctuate over time in a seasonal
manner, the baseline ten-month period may have represented
a biased estimate of year-round MRSA infection rates. There-
fore, the data analysis provided offers only preliminary evi-
dence regarding the effectiveness of the intervention.
Conclusion
A molecular MRSA detection assay permits rapid identifica-
tion of MRSA carriage in critically ill patients. It could help to
improve MRSA control strategies, especially if it is linked to
systematic on-admission screening and pre-emptive isolation
of newly admitted patients. Further controlled studies are nec-
essary to evaluate its sustained impact on MRSA cross-infec-
tion.
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ICU, although a large number of unnecessary pre-emp-
tive isolation days could be saved using the qMRSA 
test.
•  A substantial decrease in MRSA infections was seen in 
the medical ICU after increasing compliance with on-
admission screening and implementing a strategy that 
linked the rapid test to pre-emptive isolation and cohort-
ing of MRSA patients.Critical Care    Vol 10 No 1    Harbarth et al.
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